33
Participants
Start Date
October 16, 2017
Primary Completion Date
December 6, 2019
Study Completion Date
August 10, 2023
Nivolumab+Ipilimumab in combination with Anti TNF-α Certolizumab
"Induction phase: Nivolumab (1mg/kg) and Ipilimumab (3 mg/kg) injected at Week 0, 3, 6, and 9 with Certolizumab injected at the dose of 400mg at weeks 0, 3, and 6, and at the dose of 200mg at week 9.~Maintenance phase: Nivolumab (3 mg/kg) alone injected from week 12 and then every 2 weeks with Certolizumab (200 mg) injected from week 12 and then every 2 weeks."
Nivolumab+Ipilimumab in combination with Anti TNF-α Infliximab
"Induction phase: Nivolumab (1mg/kg) and Ipilimumab 3 mg/kg injected at Week 0, 3, 6, and 9 with Infliximab (5mg/kg) injected at weeks 0, 3 and 6.~Maintenance phase: Nivolumab (3 mg/kg) alone injected from week 12 and then every 2 weeks with Infliximab (5mg/kg) injected from week 14 and then every 8 weeks."
Institut Claudius Regaud IUCT-ONCOPOLE, Toulouse
Institut Claudius Regaud
OTHER